Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors
暂无分享,去创建一个
H. Shewade | Hui Zhang | K. Jeyashree | Canyou Zhang | Lixia Wang | Ren-zhong Li | Yunzhou Ruan | Caihong Xu
[1] B. Hedlund,et al. Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection , 2018, Antimicrobial Agents and Chemotherapy.
[2] H. Shewade,et al. Delay and attrition before treatment initiation among MDR-TB patients in five districts of Gujarat, India. , 2018, Public health action.
[3] H. Shewade,et al. Provider reported barriers and solutions to improve testing among tuberculosis patients ‘eligible for drug susceptibility test’: A qualitative study from programmatic setting in India , 2018, PloS one.
[4] Nyein Aye,et al. Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar , 2018, PloS one.
[5] John D Potter,et al. Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations , 2018, PloS one.
[6] Biao Xu,et al. Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China , 2018, Antimicrobial Agents and Chemotherapy.
[7] N. Ford,et al. Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[8] Sanjay Singh Chahar,et al. Treatment Initiation among Patients with Multidrug Resistant Tuberculosis in Bhopal District, India , 2017 .
[9] D. Jeon. WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea , 2017, Tuberculosis and respiratory diseases.
[10] S. Swaminathan,et al. Low pre-diagnosis attrition but high pre-treatment attrition among patients with MDR-TB: An operational research from Chennai, India , 2017, Journal of epidemiology and global health.
[11] D. Falzon,et al. The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership , 2017, PloS one.
[12] Sanjay Singh Chahar,et al. High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India , 2017, BMC Health Services Research.
[13] F. Cobelens,et al. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study , 2017, PLoS medicine.
[14] P. Memiah,et al. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies , 2017, Infectious Diseases of Poverty.
[15] C. Palanivel,et al. MDR-TB in Puducherry, India: reduction in attrition and turnaround time in the diagnosis and treatment pathway. , 2016, Public health action.
[16] D. Moore,et al. The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review , 2016, BMC Infectious Diseases.
[17] H. Shewade,et al. The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh , 2015, PloS one.
[18] G. Roy,et al. MDR-TB screening in a setting with molecular diagnostic techniques: who got tested, who didn't and why? , 2015, Public health action.
[19] P. Curmi,et al. Members of the Chloride Intracellular Ion Channel Protein Family Demonstrate Glutaredoxin-Like Enzymatic Activity , 2015, PloS one.
[20] N. Pallewatte,et al. Management of previously treated tuberculosis patients in Kalutara district, Sri Lanka: how are we faring? , 2014, Public health action.
[21] Fei Huang,et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data , 2014, The Lancet.
[22] Y. Li,et al. Are We Doing Enough to Stem the Tide of Acquired MDR-TB in Countries with High TB Burden? Results of a Mixed Method Study in Chongqing, China , 2014, PloS one.
[23] S. Egwaga,et al. Are sputum samples of retreatment tuberculosis reaching the reference laboratories? A 9-year audit in Tanzania. , 2013, Public health action.
[24] S. Satyanarayana,et al. Linkage of Presumptive Multidrug Resistant Tuberculosis (MDR-TB) Patients to Diagnostic and Treatment Services in Cambodia , 2013, PloS one.
[25] S. Okada,et al. The Identification of a Small Molecule Compound That Reduces HIV-1 Nef-Mediated Viral Infectivity Enhancement , 2011, PloS one.
[26] A. Harries,et al. Operational Challenges in Diagnosing Multi-Drug Resistant TB and Initiating Treatment in Andhra Pradesh, India , 2011, PloS one.
[27] A. Harries,et al. Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[28] C. Dolea,et al. World Health Organization , 1949, International Organization.